So, Deb G took over Sanofi’s US vaccine division at mid-year 2022. Great to see she’s already making her mark on the business:
Sanofi is used to reporting strong Dupixent sales growth by now, but a decline in flu vaccine revenues brought an unusual twist for the drugmaker in the fourth quarter.
Sanofi's fourth-quarter vaccine sales slipped 16% to 1.7 billion euros ($1.83 billion). The decline was expected, Sanofi's vaccines head Thomas Triomphe explained on a conference call, citing a "challenging vaccination environment marked by both patient and provider fatigue."
Within the category, sales of influenza vaccines declined by a whopping 32% to 802 million euros because the drugmaker collected a higher proportion of its revenues earlier in the season.
Despite the quarterly drop, Sanofi's vaccine sales for the full year increased by 6.3% to 7.2 billion euros. The company has new manufacturing capacity in the U.S. that helped its influenza business deliver a "record" year despite the fourth-quarter troubles, the company said in a press release.
Sanofi is used to reporting strong Dupixent sales growth by now, but a decline in flu vaccine revenues brought an unusual twist for the drugmaker in the fourth quarter.
Sanofi's fourth-quarter vaccine sales slipped 16% to 1.7 billion euros ($1.83 billion). The decline was expected, Sanofi's vaccines head Thomas Triomphe explained on a conference call, citing a "challenging vaccination environment marked by both patient and provider fatigue."
Within the category, sales of influenza vaccines declined by a whopping 32% to 802 million euros because the drugmaker collected a higher proportion of its revenues earlier in the season.
Despite the quarterly drop, Sanofi's vaccine sales for the full year increased by 6.3% to 7.2 billion euros. The company has new manufacturing capacity in the U.S. that helped its influenza business deliver a "record" year despite the fourth-quarter troubles, the company said in a press release.